rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozygous deletion.
|
30972500 |
2019 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozygous deletion.
|
30972500 |
2019 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244).
|
24132923 |
2013 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244).
|
24132923 |
2013 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV).
|
28928859 |
2017 |
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
rs121913500
|
|
|
0.040 |
GeneticVariation |
BEFREE |
As the presence of the p.R132H mutation in the IDH1 gene seems to be a more powerful prognostic marker than O(6)-methylguanine-DNA methyltransferase promoter status, we evaluated the presence of IDH1 mutation in Polish patients with astrocytoma, glioblastoma, oligoastrocytoma, ganglioglioma, oligodendroglioma, and ependymoma.
|
23934769 |
2014 |
rs118101777
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
rs118101777
|
|
|
0.020 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
rs2297440
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Moreover, the stratified analyses showed a decreased risk of astrocytoma associated with RTEL1 rs6089953, rs6010620 and rs2297440 (p trend = 0.022, p trend = 0.042, p trend = 0.029, respectively) as well as an increased risk of this subtype associated with RTEL1 rs4809324 (p trend = 0.033).
|
26014354 |
2015 |
rs2297440
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In the recessive model, we found two tSNPs (rs2297440 and rs6010620) associated with increased astrocytoma risk.
|
23812731 |
2013 |
rs2431689
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Rs17057846, rs1582417, and rs2431689 polymorphisms were associated with prognosis of astrocytoma, and rs1582417, rs17057846, and rs58747524 variants were associated with the survival rate in patients with low-grade glioma (I to II).
|
31513017 |
2020 |
rs12594
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox regression analysis shows that RYR2 rs12594 AA genotype and AG genotype were associated with OS of astrocytoma (AG genotype: HR = 1.62, 95% CI 1.04-2.53, p = 0.034; AA genotype: HR = 1.70, 95% CI 1.08-2.68, p = 0.021).
|
31440994 |
2019 |
rs16835904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis shows that RYR2 rs16835904 TC-TT genotype facilitated the risk of astrocytoma in male (OR = 1.93, 95% CI 1.15-3.24, p = 0.011).
|
31440994 |
2019 |
rs17522122
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
rs2378456
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In recessive model, the patients with LPP rs2378456 CC genotype increased the risk of astrocytoma (OR = 1.43, 95% CI 1.01-2.02, p = 0.042).
|
31440994 |
2019 |
rs4261436
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
rs7115578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs7115578 AG genotype represented a poorer prognosis of glioma (HR = 1.24, P=0.033) and astrocytoma (log-rank P=0.037, HR = 1.31, P=0.036).
|
31652449 |
2019 |